Key result
The number of publications regarding sacubitril/valsartan increased sharply between 2015 and 2021, with the United States authoring over 40% of the 1,309 retrieved articles.
Why the study?
Sacubitril/valsartan is widely used for heart failure with reduced ejection fraction, but its effectiveness remains under investigation, and few bibliometric studies have systematically analyzed its application.
Systematic Review (n=1,309)
This bibliometric analysis highlights the rapid growth in sacubitril/valsartan research since 2015, driven largely by US institutions and focused primarily on heart failure clinical trials and mechanisms.
Answers are grounded in this paper and cite their sources.
Supports timely evidence synthesis for sacubitril/valsartan in heart failure; leaves open the impact of US dominance on global priorities.
BACKGROUND: Sacubitril/valsartan has been approved for the treatment of heart failure (HF) patients with reduced ejection fraction; since then, it gradually became a new star drug in the therapy of HF. Nevertheless, the effectiveness of sacubitril/valsartan remains under investigation. Thus far, only a few bibliometric studies have systematically analyzed the application of sacubitril/valsartan. METHODS: Publications on sacubitril/valsartan were retrieved from the Web of Science Core Collection on April 29, 2021. Data were analyzed using Microsoft Excel 2019 (Redmond, WA), VOS viewer (Redmond, WA), and Cite Space V (Drexel University, Philadelphia, PA). RESULTS: A total of 1309 publications on sacubitril/valsartan published from 1995 to 2021 were retrieved. The number of publications regarding sacubitril/valsartan increased sharply in the last 6 years (2015-2021), and American scholars authored >40% of those publications. Most were published in the European Journal of Heart Failure, the United States was the bellwether with a solid academic reputation in this area. Solomon published the highest number of related articles and was the most frequently cited author. "Heart failure" was the leading research hotspot. The keywords, "inflammation," "fibrosis," and "oxidative stress" appeared most recently as research fronts. CONCLUSIONS: Research attention should be focused on clinical trial outcomes. Considering its effectiveness in HF, the mechanisms and further applications of sacubitril/valsartan may become research hotspots in the future and should be closely examined.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2022) conducted a systematic review in Heart failure (sacubitril/valsartan research) (n=1,309). Sacubitril/valsartan research publications was evaluated on Publication output and temporal trend. The number of publications regarding sacubitril/valsartan increased sharply between 2015 and 2021, with the United States authoring over 40% of the 1,309 retrieved articles.
Synapse has enriched 10 related papers. Consider them for comparative context: